Trial | NCT00898950  Report issue

Title

Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes
The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    21
This study was set up to assess the effects of different doses of aspirin when compared with placebo (dummy drug), used sequentially over a 2 week study period with a 2 week wash-out (rest period) in between, in people with type-2 diabetes and high cardiovascular risk. Specifically, its effects on different factors which are thought to contribute to diabetes such as insulin resistance (body's ability to effectively use insulin), dysglycaemia (excess glucose in the blood), oxidative stress (effects from accumulation of by-products of metabolism), endothelial function (function of lining of blood vessels) and inflammation were studied.
Study Started
Aug 31
2004
Primary Completion
Jul 31
2006
Study Completion
Jul 31
2006
Last Update
May 12
2009
Estimate

Drug Aspirin

Aspirin 75mgs/day orally for 2 weeks.

  • Other names: acetyl salicylic acid

Drug Aspirin

300mgs/day orally for 2 weeks

  • Other names: acetyl salicylic acid

Drug Aspirin

aspirin 900mgs QID orally for 2 weeks

  • Other names: acetyl salicylic acid

Other placebo tablet

placebo tablet with lactose and excipients.

Aspirin low dose Experimental

Effects of using aspirin 75 mgs/day for 2 weeks.

Aspirin medium dose Experimental

Effects of using aspirin 300 mgs/day

aspirin high dose Experimental

aspirin 900mgs QID orally for 2 weeks

placebo Placebo Comparator

Criteria 

Inclusion Criteria:

diabetes type 2
age > 18 and < 70
high cardiovascular risk

Exclusion Criteria:

presence of active/established cardiovascular disease (ischaemic heart disease, cerebrovascular disease or peripheral vascular disease)
insulin treatment
patients with known peptic ulcer disease or those on anti-coagulation
significant renal impairment
aspirin intolerance
use of anticoagulants
significant liver disease
No Results Posted